Ocuphire Pharma Results Presentation Deck

27 Landscape of Systemic Therapies for Diabetic Retinopathy Ocuphire's APX3330 is the Most Advanced Oral Drug Moving into EOP2 Mtg and Phase 3 Company Lilly aerpio pharmacei B BAYER E R Drug LY333531 ÇAKB-9778 Ocuphire APX3330 OALKAHESTⓇ AKST4290 Roche RG7774 Boehringer Ingelheim Valo OPL-0401 BAY1101042 Guanylate Cyclase activator Protein Kinase C inhibitor Tie2 www.clinicaltrials.gov Target/MOA Ref-1 inhibitor (Anti-VEGF and Anti-inflammatory) CCR3 Eotaxin inhibitor BI 1467335 AOC3 CB2 receptor (cannabinoid) ROCK 1/2 inhibitor Indication DR DR DR DR DR DR DR DR Route of Administration Oral Subcutaneous Oral Oral Oral Oral Oral Oral Phase 1 Phase 2 Phase 3 X 2006 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ X 2019 ✓ X 2022 X 2021 Note Two Tyrosine Kinase and a Plasma Kallikrein Inhibitors failed as orals in Phase 2 due to dose limiting adverse events (e.g., liver and cardiovascular) Primary Endpoint/ Secondary Endpoints 2002: BCVA 3-line 2017: 2-step DRSS @wk24 2020: 2-step DRSS @wk24 2021: 2-step DRSS @wk24 2021: 2-step DRSS @wk24 2020: 2-step DRSS @wk36 2017: Primary:safety@wk12 Secondary: 2-step DRSS@wk12 2021: 2-step DRSS @wk24 Completed Ongoing X Discontinued Ocuphire FHPERS

View entire presentation